Biogen Inc. (BIIB)
NASDAQ: BIIBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
BIIB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $32.82B
- P/E (TTM)
- 39.46
- Forward P/E
- 13.43
- EPS (TTM)
- $5.63
- Dividend yield
- None
- 52-week range
- 138.00 – 230.49
- Day range
- 221.40 – 228.00
- Volume / Avg
- 1.30M / 1.06M
- Beta
- —
- Shares outstanding
- 147.75M
- Next earnings
- Oct 28, 2026
52-week range
BIIB stock today
On Oct 7, BIIB ended the session at $222.15, shedding $0.74 (0.33%), versus the S&P 500's 0.22% decline. At this level, BIIB sits near the top of its 52-week range of $138.00 to $230.49: 3.6% below the high, set on Sep 28, 2026 and 61.0% above the low. BIIB is up 26.2% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 45.9%.
At 39.5x trailing earnings, Biogen trades above the peer-group median of 32.4x. Its forward P/E of 13.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 28 before the market opens; analysts expect EPS of $2.10.
Summary generated from market data by MetaCap's automated system. Methodology
About Biogen
Company profileBiogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Christopher A. Viehbacher
- Headquarters
- Cambridge, MA
- Employees
- 7,500
- Website
- biogen.com
Financial highlights
Full financialsIn fiscal 2025, Biogen generated $9.89 billion in revenue, up 2.2% from fiscal 2024. Net income was $1.29 billion (-20.8% year over year), for a net margin of 13.1% versus a median of 16.9% in the prior 5 years. Gross margin was 75.7% (down from 76.1%).
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B |
| Growth | +2.22% | -1.62% | -3.32% | -7.36% | -18.32% |
| Net income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B |
| EPS (diluted) | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 |
Analyst forecast
ForecastConsensus (35 analysts)
buy
Avg. price target
$238.18+7.22%
- Strong buy 3
- Buy 19
- Hold 12
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 28, 2026
- EPS estimate
- $2.10
- Last reported (Q1 2026)
- Apr 29, 2026
- EPS actual vs est.
- $2.15 vs —
BIIB news
All BIIB newsBiogen peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BNTXBioNTech SE ADR | 95.25 | -0.50% | $23.93B | vs BIIB |
| RVMDRevolution Medicines Inc. | 200.87 | +0.50% | $43.05B | vs BIIB |
| NBIXNeurocrine Biosciences Inc. | 143.47 | -1.40% | $14.58B | vs BIIB |
| EXELExelixis Inc. | 58.44 | +0.19% | $14.48B | vs BIIB |
| HALOHalozyme Therapeutics Inc. | 110.79 | +0.98% | $12.57B | vs BIIB |
| TECHBio-Techne Corp | 72.53 | +0.14% | $11.37B | vs BIIB |
| RGENRepligen Corporation | 167.22 | -4.37% | $10.62B | vs BIIB |
| IBRXImmunityBio Inc. | 9.75 | +0.62% | $10.33B | vs BIIB |
Indexes, lists and sector
Index membership
Biogen stock FAQ
What is Biogen's stock price today?
BIIB last traded at $222.15 as of Oct 7, 4:00 PM EDT, down 0.33% on the day. Prices are delayed at least 15 minutes.
Does Biogen pay a dividend?
No. Biogen does not currently pay a regular cash dividend.
When is Biogen's next earnings date?
Biogen is expected to report earnings on Wednesday, October 28, 2026. Analysts expect EPS of $2.10.
What is BIIB's P/E ratio?
BIIB trades at a trailing P/E ratio of 39.46 and a forward P/E of 13.43, compared with a median of 32.4 for its closest peers.
Is Biogen in the S&P 500?
Yes. Biogen (BIIB) is a constituent of the S&P 500 index.
Who is Biogen's CEO?
Mr. Christopher A. Viehbacher is the chief executive officer of Biogen Inc., which has about 7,500 employees.
Has BIIB ever split its stock?
Yes. The most recent BIIB stock split was a 3-for-1 split on Jan 18, 2001, one of 2 splits on record.